Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.760 +0.050 (+2.92%)

Official Closing Price Updated: 8:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 20, 2021

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

Via InvestorPlace

Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

December 20, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

November 10, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

November 30, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021

November 03, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

November 15, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy ↗

October 21, 2021

Photo by Daniil Kuželev on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

October 26, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed ↗

October 01, 2021

Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting...

Via Benzinga

Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021

October 18, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021

September 20, 2021

From Lineage Cell Therapeutics

Via Business Wire

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

September 30, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

38 Stocks Moving In Wednesday's Mid-Day Session ↗

September 15, 2021

Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of...

Via Benzinga

Topics Intellectual Property

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

53 Biggest Movers From Yesterday ↗

September 16, 2021

Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation...

Via Benzinga

Topics Initial Public Offering

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

September 15, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

September 13, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Appointment of General Counsel

September 01, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript ↗

August 13, 2021

LCTX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs

August 12, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

August 11, 2021

Image by Rudy and Peter Skitterians from Pixabay Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to...

Via Benzinga

Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021

August 10, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021

August 05, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements ↗

July 20, 2021

Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry...

Via Benzinga

OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

July 20, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

July 13, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes

June 28, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing

June 22, 2021

From Lineage Cell Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.